Last reviewed · How we verify
HEC53856
At a glance
| Generic name | HEC53856 |
|---|---|
| Also known as | HEC53856 capsule |
| Sponsor | Sunshine Lake Pharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia (PHASE1)
- Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis. (PHASE1)
- HEC53856 Phase 1 Study - Single and Multiple Oral Dosing in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HEC53856 CI brief — competitive landscape report
- HEC53856 updates RSS · CI watch RSS
- Sunshine Lake Pharma Co., Ltd. portfolio CI